Synthesis and evaluation of novel dual GSK-3β/HDAC inhibitor as an anti-Alzheimer agent
Implementing Organization
Principal Investigator
Dr. Abha Sharma
Associate Professor
|
National Institute of Pharmaceutical Education and Research, Raebareli
About
Alzheimer's disease (AD) is a multifactorial neurodegenerative disorder with an expected number of 152 million people by 2050. A multi-target strategy is considered effective for designing new molecules to modulate AD's interconnected targets. A dual classical GSK-3β/epigenetic HDAC6 inhibitor is designed for synthesis and biological study. Preliminary in silico studies show promising properties, binding affinity, and toxicity profile. The proposed four multistep schemes will synthesize the molecules, with the aim of discovering lead molecules for AD treatment. This research area is limited to one international study and no report from India.
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.